Dual receptor peptide agonist

Survodutide

Name: Survodutide
Price: 369 USD

Survodutide is investigated as a glucagon and GLP-1 receptor dual agonist. The linked phase 2 trial studies weight-related metabolic outcomes.

BLOPEP vial — representative image — Representative image

Quantity per vial

Select variantCompare prices and choose a variant to set the quantity and add it to your quote.

5 mgper vial$369.00/ box10 mgper vial$549.00/ box

Subtotal excludes freight and taxes. Availability and final terms are confirmed in the quote. Commercial and shipping terms

Mechanism and findings →

Mechanism and findings

Human study · Study formulation · Adults with BMI at least 27, without diabetes

Body-weight endpoint

The phase 2 study assessed 46-week weight change. Substantial discontinuation and gastrointestinal adverse events limit interpretation of efficacy alone.

le et al., 2024 →

Literature findings; refer to the model and formulation studied.

Mechanism of action

Survodutide — dual receptor peptide agonist. The literature identity must be matched to the documented chemical form and composition of the supplied material.

Combined GLP-1/glucagon agonism was evaluated in a dose trial with escalation and maintenance. Planned-group analysis and analysis by exposure actually received are distinct. Discontinuations and gastrointestinal events accompany interpretation of the 46-week endpoints.

GLP-1R / GCGR

le et al., 2024

Studied findings 1

Human study · Study formulation

Body-weight endpoint

Adults with BMI at least 27, without diabetes

The phase 2 study assessed 46-week weight change. Substantial discontinuation and gastrointestinal adverse events limit interpretation of efficacy alone.

View context

Study design: Original-study abstract; experimental design described in linked source
Sample scope / arm: Not extracted; consult original study
Comparator: See original-study context
Experimental context (not instructions for use): Abstract-level extraction; full methods and tables still require review.
Source section / table / abstract: Abstract

Evidence concerns the studied material and model, not the supplied BLOPEP batch.

le et al., 2024

Sources and studies 1